The scope of the #SCOPE2019

February 27, 2019

The scope of the #SCOPE2019

10th Annual SCOPE Summit was held on 18 – 21 February in Orlando, Florida.

If you have missed it for any reason, we are here to fill you in!

Usually, all the insights we gather through an event are of two kinds: current industry problems and upcoming trends. This time we begin with Problems.

Main problems raised:

  • Study speed (study start-up, site selection, patients enrollment, etc.)
  • Study cost
  • Data Bulk
  • Visibility/transparency and predictiveness/forecast (metrics, KPIs, dashboards)
  • Multiple systems used for one study lead to lack of transparency
  • Delayed actions/responses
  • Unified vs. Integrated (the systems should be integrable)
  • Design study the sponsors/CROs wants to do, not the way technology imposes

Main problems of payment process raised:

General:For sites:For sponsor:
Data quality
Payment frequency
Negotiating
Invoice generation speed
Cash flow
Financial visibility
Administrative burden (revisions, reparation, etc.)
Payment Accuracy (overpayment)
Global financial visibility & control
Predictability
Processing and adjunction
Support burden

And continue with Trends:

Main trends discussed:

  • Virtual (Remote/Decentralized) Clinical Trials
  • Focus on outcomes, not inputs
  • Predictive analytics in Clinical Trials
  • Metrics (ICH E6 R2 requires use of metrics by sites and sponsors)
  • More use of outsourcing models
  • Partnership/Collaboration – treat providers as partners
  • Without executive support and sponsorship changes aren’t possible

Several presentations were dedicated to Remote/Virtual Clinical Trials theme. The main benefits of virtual trials are:

  • Decrease in the number of investigator sites
  • Decrease in price of procedures and site staff
  • Decrease of start-up fees
  • Increase of software and device use

Remote Clinical Trials is trending, as it allows to cut the costs of trials.

Lead sessions by pharma/biotech speakers:

Lead sessions by vendors:

General statistics:

See you there next year!

Blog

January 23, 2025
Flex Databases at EUCROF 2025

We are thrilled to announce that Flex Databases is a proud sponsor of EUCROF 2025, taking place from February 2-4, 2025! Our team members, Tamara Prekodravac and Evgenia Michalchuk-Vrablik, will represent us at this prestigious event, where industry leaders come together to drive innovation and collaboration in clinical research. This year’s event will cover important […]

January 15, 2025
How Flex Databases’ QMS Aligns with ICH E6(R3) GCP Guidelines

On January 14, 2025, the International Council for Harmonisation (ICH) took a major step forward in clinical trials management with the release of the updated E6(R3) Good Clinical Practice (GCP) guidelines. This milestone reflects the industry’s commitment to enhancing the quality, reliability, and compliance of clinical research. At Flex Databases, we’re proud to offer a […]

December 19, 2024
Product Updates: December, 2024

We are excited to announce several new features and improvements to Flex Databases’ modules. These updates aim to streamline workflows, enhance usability, and improve overall efficiency for our users. Here’s an overview of the latest developments and their benefits. Trial Master File (TMF) Duplicates Search: Files Content Comparison Path: Trial Master File → (open project) […]

December 18, 2024
How Clinical Trial Sites Can Meet Sponsor Expectations in 2025

Clinical trials are becoming more complex every year, and sponsors are raising the bar for what they expect from sites. They want faster processes, more accurate data, and better ways to keep patients engaged – all while staying compliant with ever-evolving regulations. As we look ahead to 2025, these demands will only grow. New technologies […]

Contact us

Get in touch to discuss compliance, implementation, demos, pricing

We are here for all of your questions! Tell us more about yourself and we will organize a tailored live demo to show how you can power up your clinical trials processes with Flex Databases.